Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors Poster Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors Certara2019 年 5 月 2 日
Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models Poster Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models Certara2019 年 4 月 22 日
Development of a Physiologically-Based Pharmacokinetic Model for Topical Lidocaine in Order to Predict Systemic Absorption in Healthy Volunteers, Geriatrics, and Pediatrics Poster Development of a Physiologically-Based Pharmacokinetic Model for Topical Lidocaine in Order to Predict Systemic Absorption in Healthy Volunteers, Geriatrics, and Pediatrics Certara2019 年 4 月 22 日
Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients Poster Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients Certara2019 年 4 月 22 日
Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies Poster Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies Certara2019 年 4 月 22 日
Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation Poster Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation Certara2019 年 4 月 22 日
Real world evidence marches forward in drug development Blog Real world evidence marches forward in drug development The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm…Certara2019 年 3 月 20 日
How to Perform IVIVC for Extremely Long Acting Drugs On-Demand Webinar How to Perform IVIVC for Extremely Long Acting Drugs Watch this webinar to learn how to use in vitro and in vivo models to…Certara2019 年 2 月 22 日
Managing immunogenicity using quantitative systems pharmacology Blog Managing immunogenicity using quantitative systems pharmacology The Challenge of Immunogenicity in Biologics Drug Development Biologic drug development is a rapidly evolving…Certara2019 年 2 月 22 日
PBPK’s Pivotal Role in Modern Drug Development: Busting Common Myths and Misconceptions White Paper PBPK’s Pivotal Role in Modern Drug Development: Busting Common Myths and Misconceptions This white paper addresses common PBPK myths and misconceptions and demonstrates how this approach is…Certara2019 年 2 月 4 日